NCT04119336View on ClinicalTrials.gov

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 14, 2020

Primary Completion Date

November 12, 2020

Study Completion Date

March 30, 2022

Conditions
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Interventions
DRUG

Nivolumab

Given intravenously once per cycle

DRUG

Ixazomib

Given orally on days 1, 8, 15.

DRUG

Dexamethasone

Given orally on days 1, 8, 15, 22

DRUG

Cyclophosphamide

Given intravenously on days 1, 8, 15.

Trial Locations (2)

02114

Massachusetts General Hospital Cancer Center, Boston

01923

Mass General/North Shore Cancer Center, Danvers

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Takeda Pharmaceuticals North America, Inc.

INDUSTRY

lead

Andrew Yee, MD

OTHER